Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (12) 12
index medicus (12) 12
female (10) 10
male (10) 10
middle aged (9) 9
adult (8) 8
interferon-alpha - therapeutic use (7) 7
polyethylene glycols - therapeutic use (7) 7
recombinant proteins - therapeutic use (7) 7
time factors (6) 6
treatment outcome (6) 6
aged (5) 5
antiviral agents - therapeutic use (5) 5
care and treatment (5) 5
drug therapy, combination (5) 5
gastroenterology & hepatology (5) 5
ribavirin - therapeutic use (5) 5
chronic hepatitis-c (4) 4
genotype (4) 4
hiv infections - drug therapy (4) 4
interferon-alpha - adverse effects (4) 4
italy (4) 4
polyethylene glycols - adverse effects (4) 4
prospective studies (4) 4
recombinant proteins - adverse effects (4) 4
aged, 80 and over (3) 3
antiviral agents - adverse effects (3) 3
hepacivirus - drug effects (3) 3
hepacivirus - genetics (3) 3
hepatitis (3) 3
hepatitis c - drug therapy (3) 3
hepatitis c, chronic - drug therapy (3) 3
hiv infections - virology (3) 3
infected patients (3) 3
interferon-alpha - administration & dosage (3) 3
oncology (3) 3
polyethylene glycols - administration & dosage (3) 3
recombinant proteins - administration & dosage (3) 3
ribavirin - administration & dosage (3) 3
ribavirin - adverse effects (3) 3
rna, viral - blood (3) 3
sustained response (3) 3
sustained virological response (3) 3
viral load (3) 3
weight-based ribavirin (3) 3
abridged index medicus (2) 2
adolescent (2) 2
alpha-2a plus ribavirin (2) 2
analysis (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
antiviral agents - administration & dosage (2) 2
antiviral therapy (2) 2
cancer (2) 2
chemotherapy (2) 2
coinfection (2) 2
coinfection - drug therapy (2) 2
combination therapy (2) 2
disease-free survival (2) 2
dna, viral - blood (2) 2
entecavir (2) 2
gastroenterology and hepatology (2) 2
hepatitis b (2) 2
hepatitis b virus - genetics (2) 2
hepatitis c - complications (2) 2
hepatitis c, chronic - virology (2) 2
hiv infections - complications (2) 2
hiv-1 - drug effects (2) 2
human-immunodeficiency-virus (2) 2
infectious diseases (2) 2
interferon (2) 2
italy - epidemiology (2) 2
lamivudine (2) 2
liver-disease (2) 2
natural-history (2) 2
patients (2) 2
peginterferon (2) 2
peginterferon alfa-2a (2) 2
peginterferon alpha-2a (2) 2
pharmacology & pharmacy (2) 2
quality-of-life (2) 2
recurrence (2) 2
research (2) 2
therapy (2) 2
trial (2) 2
tumors (2) 2
virology (2) 2
virus diseases (2) 2
virus-infection (2) 2
young adult (2) 2
1506 (1) 1
2nd-line treatment (1) 1
610 medicine & health (1) 1
9 mg (1) 1
[ sdv ] life sciences [q-bio] (1) 1
[sdv]life sciences [q-bio] (1) 1
adjuvant chemotherapy (1) 1
age factors (1) 1
aging (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study
by Zambetti, Milvia and Montemurro, Filippo and Morandi, Paolo and Zamagni, Claudio and Brandes, Alba A and Bisagni, Giancarlo and Cagossi, Katia and Bengala, Carmelo and Gori, Stefania and Iannacone, Claudio and Stell, Alessia and Gianni, Luca
European Journal of Cancer, ISSN 0959-8049, 12/2018, Volume 105, pp. 61 - 70
Subcutaneous trastuzumab (H SC) is a valuable alternative to the intravenous formulation. This study assessed H SC safety and tolerability in human epidermal... 
Early/locally advanced breast cancer | Subcutaneous trastuzumab | Cardiotoxicity | Safety | HER2 | ADJUVANT CHEMOTHERAPY | ONCOLOGY | PLUS | Antimitotic agents | Care and treatment | Safety and security measures | Analysis | Oncology, Experimental | Breast cancer | Research | Antineoplastic agents | Cancer | Slopes | Therapy | Intravenous administration | Injection | Congestive heart failure | Disease control | Patients | ErbB-2 protein | Heart rate | Chemotherapy | Epidermal growth factor | Anaphylaxis | Anthracycline | Pleuropericarditis | Ventricle | Taxanes | Growth factors | Trastuzumab | Ejection
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Long‐term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open‐label, cohort study
by Gragnani, Laura and Fognani, Elisa and Piluso, Alessia and Boldrini, Barbara and Urraro, Teresa and Fabbrizzi, Alessio and Stasi, Cristina and Ranieri, Jessica and Monti, Monica and Arena, Umberto and Iannacone, Claudio and Laffi, Giacomo and Zignego, Anna Linda and MaSVE Study Grp and MaSVE Study Group
Hepatology, ISSN 0270-9139, 04/2015, Volume 61, Issue 4, pp. 1145 - 1153
Limited data are available about the efficacy of antiviral treatment in hepatitis C virus (HCV)–associated mixed cryoglobulinemia (MC), especially concerning... 
B-CELLS | HEPATITIS-C VIRUS | ANTIVIRAL THERAPY | II CRYOGLOBULINEMIA | SUSTAINED RESPONSE | RITUXIMAB | INFECTED PATIENTS | VASCULITIS | LIVER-DISEASE | GASTROENTEROLOGY & HEPATOLOGY | INTERFERON THERAPY | Recombinant Proteins - therapeutic use | Prospective Studies | Hepatitis C - drug therapy | Antiviral Agents - therapeutic use | Humans | Middle Aged | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Male | Cryoglobulinemia - virology | Cryoglobulinemia - complications | Polyethylene Glycols - therapeutic use | Time Factors | Female | Hepatitis C - complications | Drug Therapy, Combination | Hepacivirus | Cohort Studies | Hepatitis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Prevalence of fatigue in Parkinson disease and its clinical correlates
by Stocchi, Fabrizio and Abbruzzese, Giovanni and Ceravolo, Roberto and Cortelli, Pietro and DʼAmelio, Marco and De Pandis, Maria F and Fabbrini, Giovanni and Pacchetti, Claudio and Pezzoli, Gianni and Tessitore, Alessandro and Canesi, Margherita and Iannacone, Claudio and Zappia, Mario and FORTE Study Grp and FORTE Study Group and For the FORTE Study Group
Neurology, ISSN 0028-3878, 07/2014, Volume 83, Issue 3, pp. 215 - 220
OBJECTIVE:To assess in a noninterventional setting the prevalence and severity of fatigue in patients with Parkinson disease (PD). METHODS:This was a... 
DEPRESSION | IMPACT | NONMOTOR SYMPTOMS | DISORDERS | PHYSICAL-ACTIVITY | QUALITY-OF-LIFE | CLINICAL NEUROLOGY | Severity of Illness Index | Depression - physiopathology | Depression - epidemiology | Prevalence | Age Factors | Cross-Sectional Studies | Humans | Middle Aged | Male | Parkinson Disease - physiopathology | Fatigue - epidemiology | Sleep Wake Disorders - epidemiology | Time Factors | Aged, 80 and over | Fatigue - physiopathology | Parkinson Disease - epidemiology | Adult | Female | Italy - epidemiology | Aged | Parkinson Disease - classification | Sleep Wake Disorders - physiopathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B
by Lampertico, Pietro and Viganò, Mauro and Di Costanzo, Giovan Giuseppe and Sagnelli, Evangelista and Fasano, Massimo and Di Marco, Vito and Boninsegna, Sara and Farci, Patrizia and Fargion, Silvia and Giuberti, Tiziana and Iannacone, Claudio and Regep, Loredana and Massetto, Benedetta and Facchetti, Floriana and Colombo, Massimo and PegBeLiver Study Group and on behalf of the PegBeLiver Study Group
Gut, ISSN 0017-5749, 02/2013, Volume 62, Issue 2, pp. 290 - 298
Objective Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with... 
Recombinant Proteins - therapeutic use | Humans | Middle Aged | Polyethylene Glycols - adverse effects | Male | Alanine Transaminase - blood | Recombinant Proteins - adverse effects | Polyethylene Glycols - therapeutic use | Lamivudine - adverse effects | Hepatitis B, Chronic - genetics | Time Factors | Lamivudine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Hepatitis B, Chronic - blood | Drug Therapy, Combination | Hepatitis B virus - immunology | Antiviral Agents - therapeutic use | Anti-HIV Agents - adverse effects | Interferon-alpha - therapeutic use | Treatment Outcome | DNA, Viral - blood | Hepatitis B, Chronic - drug therapy | Antiviral Agents - adverse effects | Hepatitis B virus - genetics | Interferon-alpha - adverse effects | Hepatitis B e Antigens - blood
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a
by Rijckborst, Vincent and Hansen, Bettina E and Ferenci, Peter and Brunetto, Maurizia R and Tabak, Fehmi and Cakaloglu, Yilmaz and Lanza, A. Galeota and Messina, Vincenzo and Iannacone, Claudio and Massetto, Benedetta and Regep, Loredana and Colombo, Massimo and Janssen, Harry L.A and Lampertico, Pietro
Journal of Hepatology, ISSN 0168-8278, 2012, Volume 56, Issue 5, pp. 1006 - 1011
Background & Aims It was recently demonstrated that none of the hepatitis B e antigen (HBeAg)-negative patients without any serum hepatitis B surface antigen... 
Gastroenterology and Hepatology | Immunomodulator | HBV genotype | Nucleos(t)ide analogues | Quantitative HBsAg | HBV therapy | Peginterferon | LAMIVUDINE | ENTECAVIR | SUSTAINED RESPONSE | GENOTYPE | CHRONIC HEPATITIS-B | GASTROENTEROLOGY & HEPATOLOGY | Recombinant Proteins - therapeutic use | Predictive Value of Tests | Antiviral Agents - therapeutic use | Humans | Middle Aged | Interferon-alpha - therapeutic use | Genotype | Male | Treatment Outcome | Biomarkers - blood | Hepatitis B - blood | Withholding Treatment | Polyethylene Glycols - therapeutic use | Hepatitis B Surface Antigens - blood | DNA, Viral - blood | Dose-Response Relationship, Drug | Time Factors | Hepatitis B - drug therapy | Hepatitis B virus - genetics | Adult | Female | Retrospective Studies | Antigen-antibody reactions | Hepatitis | Antigens | Care and treatment | Heterocyclic compounds | DNA | Interferon | Hepatitis B
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Randomised study comparing 48 and 96 weeks peginterferon alpha-2a therapy in genotype D HBeAg-negative chronic hepatitis B
by Lampertico, P and Vigano, M and Di Costanzo, GG and Sagnelli, E and Fasano, M and Di Marco, V and Boninsegna, S and Farci, P and Fargion, S and Giuberti, T and Iannacone, C and Regep, L and Massetto, B and Facchetti, F and Colombo, M and PegBeLiver Study Grp
GUT, ISSN 0017-5749, 02/2013, Volume 62, Issue 2, pp. 290 - 298
Objective Treatment with peginterferon alpha-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with... 
E-ANTIGEN | LAMIVUDINE | ENTECAVIR | INTERFERON-ALPHA | SUSTAINED RESPONSE | RETREATMENT | GASTROENTEROLOGY & HEPATOLOGY | EPIDEMIOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update
by Bajetta, Emilio and Catena, Laura and Pusceddu, Sara and Spada, Francesca and Iannacone, Claudio and Sarno, Italo and Di Menna, Giandomenico and Dottorini, Lorenzo and Marte, Anna Maria
Neuroendocrinology, ISSN 0028-3835, 05/2018, Volume 106, Issue 4, pp. 307 - 311
Background: We previously presented data of this multicentric, phase II study showing that everolimus plus octreotide long-acting repeatable (LAR) for advanced... 
Original Paper | Octreotide long-acting repeatable | Neuroendocrine tumor | Everolimus | LUNG | RADIANT-2 | BIOLOGY | ENDOCRINOLOGY & METABOLISM | SUNITINIB | AKT | PHASE-3 | NEUROSCIENCES | Humans | Middle Aged | Kaplan-Meier Estimate | Octreotide - adverse effects | Male | Treatment Outcome | Everolimus - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Everolimus - adverse effects | Neuroendocrine Tumors - mortality | Neuroendocrine Tumors - drug therapy | Adult | Female | Aged | Octreotide - administration & dosage | Delayed-Action Preparations | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study
: Viral Hepatitis
by Gragnani, Laura and Fognani, Elisa and Piluso, Alessia and Boldrini, Barbara and Urraro, Teresa and Fabbrizzi, Alessio and Stasi, Cristina and Ranieri, Jessica and Monti, Monica and Arena, Umberto and Iannacone, Claudio and Laffi, Giacomo and Zignego, Anna Linda and for the MaSVE Study Group
Hepatology, ISSN 0270-9139, 04/2015, Volume 61, Issue 4, pp. 1145 - 1153
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Randomised study comparing 48 and 96 weeks peginterferon (alpha)-2a therapy in genotype D HBeAg-negative chronic hepatitis B
by Lampertico, Pietro and Sagnelli, Evangelista and Iannacone, Claudio and Regep, Loredana and Colombo, Massimo and Massetto, Benedetta and Di Costanzo, Giovan Giuseppe and Giuberti, Tiziana and Farci, Patrizia and Di Marco, Vito and Facchetti, Floriana and Vigano, Mauro and Fargion, Silvia and Boninsegna, Sara and Fasano, Massimo
Gut, ISSN 0017-5749, 02/2013, Volume 62, Issue 2, p. 290
  Objective Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with... 
Care and treatment | Hepatitis associated antigen | Dosage and administration | Peginterferon alfa-2a | Research | Hepatitis B | Genotype & phenotype | Hepatitis | Liver diseases | Interferon | Infections | Clinical medicine | Liver cirrhosis | Patients | Deoxyribonucleic acid--DNA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
by Danese, Silvio and Hart, Ailsa and Dignass, Axel and Louis, Edouard and D'Haens, Geert and Dotan, Iris and Rogler, Gerhard and D'Agay, Laurence and Iannacone, Claudio and Peyrin-Biroulet, Laurent
BMJ Open Gastroenterology, ISSN 2054-4774, 05/2016, Volume 3, Issue 1, p. e000092
IntroductionA study has been developed to assess the use and effectiveness of budesonide MMX for mild-to-moderate active ulcerative colitis (UC) in routine... 
Inflammatory bowel disease | Studies | Questionnaires | Product development | Joint surgery | Colon | Endoscopy | Patient satisfaction | Quality of life | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Radiotherapy for unresectable sinonasal cancers: Dosimetric comparison of intensity modulated radiation therapy with coplanar and non-coplanar volumetric modulated arc therapy
by Orlandi, Ester and Giandini, Tommaso and Iannacone, Eva and De Ponti, Elena and Carrara, Mauro and Mongioj, Valeria and Stucchi, Claudio and Tana, Silvia and Bossi, Paolo and Licitra, Lisa and Fallai, Carlo and Pignoli, Emanuele
Radiotherapy and Oncology, ISSN 0167-8140, 2014, Volume 113, Issue 2, pp. 260 - 266
Abstract Background and purpose To compare volumetric modulated arc therapy (VMAT) and intensity modulated radiation therapy (IMRT) plans for treatment of... 
Hematology, Oncology and Palliative Medicine | Normal tissue sparing | Intensity modulated radiation therapy | Target coverage | Volumetric modulated arc therapy | Dosimetric comparison | Unresectable paranasal sinus cancer | HEAD | VMAT | IMRT | TUMORS | NECK-CANCER | NASOPHARYNGEAL CARCINOMA | ONCOLOGY | NASAL CAVITY | PARANASAL SINUS CANCER | UPDATE | HELICAL TOMOTHERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Radiotherapy Dosage | Radiometry - methods | Paranasal Sinus Neoplasms - radiotherapy | Radiotherapy Planning, Computer-Assisted - methods | Humans | Radiotherapy, Intensity-Modulated - methods | Comparative analysis | Radiotherapy | Radiation | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study
by Craxì, Antonio and Piccinino, Felice and Ciancio, Alessia and Iannacone, Claudio and Deodato, Barbara and Golotta, Caterina and Ascione, Antonio
European Journal of Gastroenterology & Hepatology, ISSN 0954-691X, 04/2014, Volume 26, Issue 4, pp. 388 - 395
BACKGROUNDThis large prospective multicentre cohort study aimed to improve knowledge of therapy for chronic hepatitis C (CHC) in real clinical practice.... 
Italy | comorbidities | peginterferon a | special populations | sustained virological response | PLUS RIBAVIRIN | PEGINTERFERON ALPHA-2A | GASTROENTEROLOGY & HEPATOLOGY | peginterferon | Recombinant Proteins - therapeutic use | Recurrence | Prospective Studies | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Young Adult | Time Factors | Aged, 80 and over | Adult | Female | Hepatitis C, Chronic - epidemiology | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Comorbidity | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Remission Induction | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Italy - epidemiology | Aged | Interferon-alpha - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon‐naïve patients with HIV/HCV genotype 2/3 co‐infection in Italy
by Bruno, Raffaele and Cariti, Giuseppe and Nasta, Paola and Capetti, Amedeo and Ravasio, Veronica and Galli, Massimo and Raise, Enzo and Palmieri, Giulio and Iannacone, Claudio and Puoti, Massimo
Liver International, ISSN 1478-3223, 01/2015, Volume 35, Issue 1, pp. 120 - 129
Background & Aims Hepatitis C virus (HCV) genotype 3 (G3) is common among HIV/HCV co‐infected individuals and associated with moderate sustained virological... 
HIV infections | ribavirin | peginterferon alfa‐2a | hepatitis C | Peginterferon alfa-2a | Hepatitis C | Ribavirin | WEIGHT-BASED RIBAVIRIN | CHRONIC HEPATITIS-C | INCREASING BURDEN | HUMAN-IMMUNODEFICIENCY-VIRUS | NATURAL-HISTORY | LIVER-DISEASE | HCV INFECTION | HIV-INFECTED PATIENTS | peginterferon alfa-2a | PEGYLATED INTERFERON | ALPHA-2A PLUS RIBAVIRIN | GASTROENTEROLOGY & HEPATOLOGY | Recombinant Proteins - therapeutic use | Prospective Studies | Hepatitis C - drug therapy | Coinfection - drug therapy | Humans | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Hepacivirus - genetics | Genotype | Hepatitis C - genetics | RNA, Viral - blood | Polyethylene Glycols - therapeutic use | Drug Therapy, Combination - methods | HIV Infections - complications | HIV Infections - drug therapy | Hepatitis C - complications | Italy | Odds Ratio
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non–Small-Cell Lung Cancer in Elderly Patients
by Gridelli, Cesare and Novello, Silvia and Zilembo, Nicoletta and Luciani, Andrea and Favaretto, Adolfo Gino and De Marinis, Filippo and Genestreti, Giovenzio and Crinò, Lucio and Grossi, Francesco and Caffo, Orazio and Ferraù, Francesco and Cruciani, Giorgio and Brandes, Alba Ariela and Galetta, Domenico and Barni, Sandro and Fasola, Gianpiero and Cerea, Giulio and Ferrari, Silvia and Iannacone, Claudio and Ciardiello, Fortunato
Journal of Thoracic Oncology, ISSN 1556-0864, 05/2014, Volume 9, Issue 5, pp. 733 - 737
The aim of the present study was to evaluate the efficacy and tolerability of vandetanib plus gemcitabine (V/G) compared with gemcitabine alone in elderly... 
Non–small-cell lung cancer | Vandetanib | Gemcitabine | Elderly | Non-small-cell lung cancer | METAANALYSIS | KINASE INHIBITOR | DOCETAXEL | CHEMOTHERAPY | TRIAL | THERAPY | ONCOLOGY | RESPIRATORY SYSTEM | 2ND-LINE TREATMENT | DOUBLE-BLIND | Lung Neoplasms - drug therapy | Piperidines - administration & dosage | Double-Blind Method | Deoxycytidine - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Survival Rate | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Piperidines - adverse effects | Quinazolines - adverse effects | Aged, 80 and over | Deoxycytidine - adverse effects | Female | Quinazolines - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Deoxycytidine - analogs & derivatives | Placebos - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: Safety analysis of the OPERA study
by Pontali, Emanuele and Angeli, Elena and Cattelan, Anna M and Maida, Ivana and Nasta, Paola and Verucchi, Gabriella and Caputo, Antonietta and Iannacone, Claudio and Puoti, Massimo
Antiviral Therapy, ISSN 1359-6535, 2015, Volume 20, Issue 1, pp. 39 - 48
Background: Until recently, recommendations for HCV treatment in HIV-coinfected patients have been combination therapy with pegylated interferon (PEG-IFN) and... 
INFECTIOUS DISEASES | WEIGHT-BASED RIBAVIRIN | VIRUS-INFECTION | ANTIVIRAL THERAPY | COMBINATION THERAPY | CHRONIC HEPATITIS-C | ITPA GENE POLYMORPHISMS | SUSTAINED VIROLOGICAL RESPONSE | VIROLOGY | PEGINTERFERON ALPHA-2A | ALPHA-2A PLUS RIBAVIRIN | PHARMACOLOGY & PHARMACY | INFECTED PATIENTS | Hepatitis C, Chronic - pathology | Coinfection | Cell Count | Humans | Middle Aged | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Anemia - pathology | Male | Recombinant Proteins - adverse effects | HIV-1 - physiology | HIV Infections - pathology | Ribavirin - administration & dosage | Neutropenia - pathology | Adult | Female | Hepacivirus - physiology | Neutropenia - chemically induced | Hepacivirus - drug effects | HIV-1 - drug effects | HIV Infections - virology | Anemia - chemically induced | Thrombocytopenia - chemically induced | Hepatitis C, Chronic - drug therapy | Thrombocytopenia - pathology | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | HIV Infections - drug therapy | Interferon-alpha - adverse effects | Viral Load - drug effects
Journal Article
Details down arrow
16. Full Text Effect of Aging, Glucose Level, and HIV Viral Load on Response to Treatment with Pegylated Interferon Plus Ribavirin in HIV/HCV Co-Infected Women
by Nasta, Paola and Maida, Ivana and Cattelan, Anna Maria and Pontali, Emanuele and Angeli, Elena and Giralda, Mariarosaria and Verucchi, Gabriella and Caputo, Antonietta and Iannacone, Claudio and Puoti, Massimo and Carosi, Giampiero
Journal of Women's Health, ISSN 1540-9996, 02/2015, Volume 24, Issue 2, pp. 159 - 164
Background: This was a post-hoc analysis of the Optimized Pegylated interferons Efficacy and anti-Retroviral Approach (OPERA) study, originally designed to... 
Original Articles | VIRUS-INFECTION | CHRONIC HEPATITIS-C | LIVER FIBROSIS | NATURAL-HISTORY | OBSTETRICS & GYNECOLOGY | MEDICINE, GENERAL & INTERNAL | HEPATOCELLULAR-CARCINOMA | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | INSULIN-RESISTANCE | ESTROGEN | HCV | WOMEN'S STUDIES | MENOPAUSE | PROGRESSION | Recombinant Proteins - therapeutic use | Coinfection - drug therapy | Humans | Middle Aged | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Polyethylene Glycols - therapeutic use | Viral Load | Time Factors | Ribavirin - administration & dosage | Aging | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | HIV-1 - drug effects | HIV Infections - virology | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | RNA, Viral - analysis | Logistic Models | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | HIV Infections - complications | Glucose - metabolism | HIV Infections - drug therapy | Italy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. OPERA: Use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients
by Carosi, Giampiero and Bruno, Raffaele and Cariti, Giuseppe and Nasta, Paola and Gulminetti, Roberto and Galli, Massimo and Angarano, Gioacchino and Verucchi, Gabriella and Pontali, Emanuele and Capetti, Amedeo and Raise, Enzo and Ravasio, Veronica and Maida, Ivana and Iannacone, Claudio and Caputo, Antonietta and Puoti, Massimo
Antiviral Therapy, ISSN 1359-6535, 2014, Volume 19, Issue 8, pp. 735 - 745
Background: The Optimized Pegylated interferons Efficacy and anti-Retroviral Approach (OPERA) study aimed to assess the efficacy and safety profile of... 
ALPHA-2A | INFECTIOUS DISEASES | WEIGHT-BASED RIBAVIRIN | TELAPREVIR | COMBINATION THERAPY | CHRONIC HEPATITIS-C | HUMAN-IMMUNODEFICIENCY-VIRUS | SUSTAINED VIROLOGICAL RESPONSE | TRIAL